Updates for 2022

FDLI remains committed to providing high-quality educational programs in a way that keeps our members and event attendees safe. With this in mind, we are excited to announce that the Introduction to Drug Law and Regulation course will be a hybrid event (both in-person and virtual). Please note that all in-person plans are subject to change as needed to protect the health and safety of the FDLI community.

Explore the essentials of drug law and regulation and gain a comprehensive understanding of the administrative agencies that impact this industry. Learn about patent and exclusivity issues, Rx to OTC switches, Good Manufacturing Practices (GMP), advertising and promotion, compliance, enforcement, and related issues. Case studies, hypotheticals, and ample time for Q&A are provided.

Agenda Highlights

  • Overview of the organizational structure of the FDA
  • FDA’s regulatory process for drugs
  • New Drug Application Process (NDA)
  • Biologics and biosimilars
  • Post-approval drug safety issues
  • Advertising and promotion requirements
  • FDA’s enforcement tools and procedures

Statutes Covered

  • Federal Food, Drug & Cosmetic Act (FD&C Act)
  • Kefauver-Harris Amendments
  • Drug Price Competition and Patent Restoration Act of 1984 (Hatch-Waxman)
  • Biologics Control Act
  • Food and Drug Administration Safety and Innovation Act (FDASIA)
  • Food and Drug Administration Modernization Act (FDAMA)
  • Food and Drug Administration Act (FDAAA)
  • Biologics Price Competition and Innovation Act (BPCIA)
  • Prescription Drug User Fee Act (PDUFA)
  • Generic User Fee Amendments (GDUFA)
  • Drug Quality and Security Act (DQSA)
  • 21st Century Cures Act


Attendee Resources

These valuable takeaways will be provided onsite:

Who Should Attend

  • New legal and regulatory professionals
  • Seasoned practitioners new to the topic or wanting a refresher


Register by Fall 2022 and SAVE!

Industry & Firms

  • +$400 for non-members
  • +$100 Fall 2022


  • +$200 for non-members
  • +$100 Fall 2022


  • +$200 for non-members
  • +$100 Fall 2022


  • +$200 for non-members
  • +$100 Fall 2022


Register Now

Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari.  If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.

To ensure that FDLI is able to provide you with a seat, materials, and meals, please register for programs at least 48 hours in advance. While onsite registration is available on a “space-available” basis; late registrants are not guaranteed materials or meals.

You can transfer your registration to another person at your organization for no cost by notifying us of the change. If you notify FDLI in writing at least five business days prior to the meeting, you can cancel your registration for a full refund (less a $75 fee). Refunds will be applied against the original form of payment.  

Our event policies are listed here. If you should have any further questions, please contact us at [email protected] or 800-956-6293.

Last Year’s Agenda

All times are in Eastern Daylight Time

Curriculum Advisor:

Rebecca Dandeker, Partner, Morgan, Lewis & Bockius LLP


Preconference Primers

Preconference Primer (Virtual)
Overview of Drug Law and Regulation
Nathan Beaton, Associate, Latham & Watkins LLP
Meryl E. Bartlett, Associate, Latham & Watkins LLP

Preconference Primer (Virtual)
The New Drug Approval Process: Basic Concept
Alexandre Gapihan, Associate, Morgan, Lewis & Bockius LLP

Tuesday, November 9

11:00 AM
FDLI Welcome and Announcements
Khara L. Minter, Assistant Director, Training Programs, FDLI

11:05 AM –12:15 PM
The New Drug Approval Process: New Drug Research and Development
Marc Wagner, Associate, BakerHostetler

12:15–1:00 PM
FDA’s COVID-19 Activities
Angela M. Seaton, Partner, Shook, Hardy & Bacon LLP

1:00–1:15 PM

1:15–2:25 PM
The New Drug Approval Process: NDA Submission and Review
Elizabeth Mulkey, Senior Associate, Goodwin Procter LLP

2:25–3:35 PM
The Abbreviated NDA (ANDA), 505(b)(2) Applications, and Patent and Exclusivity Issues
Rebecca L. Dandeker, Partner, Morgan, Lewis & Bockius, LLP

3:35–3:50 PM

3:50–5:00 PM
Post-Approval Issues
Frederick A. Stearns, Partner, Kellerand Heckman LLP


Wednesday, November 10

11:00 PM
FDLI Welcome and Announcements
Khara L. Minter, Assistant Director, Training Programs, FDLI

11:05 AM–12:05 PM
Biologics and Biosimilars
Christopher Gallo, Associate, Axinn, Veltrop & Harkrider LLP

12:05–1:05 PM
Regulation of Over-the-Counter (OTC) Drugs
Deborah L. Livornese, Director, Hyman, Phelps & McNamara, PC

1:05–1:15 PM

1:15–2:15 PM
Regulation of Drug Manufacturing
Peter V. Lindsay, Partner, Paul Hastings

2:15–2:30 PM

2:30–3:30 PM
Regulation of Drug Marketing
Heather Banuelos, Counsel, King & Spalding LLP
Gillian M. Russell, Counsel, King & Spalding LLP

3:30–3:45 PM

3:45–5:00 PM
Violations and Enforcement
Tiffany Humphries, Senior Associate, BakerMcKenzie

5:00 PM

Continuing Legal Education

FDLI applies for CLE credits in Ohio and Virginia. These CLE approvals may also be honored by other states; please check with your bar association for guidance. The CLE credits will be posted as they are granted and you can request to be notified when approval is received.


Location and Overnight Accommodations

Conference Location

1032 15th Street, NW
Washington, DC 20005

Parking and Public Transportation

Overnight Accommodations

Please contact the Conference Department with any accessibility requirements or dietary restrictions, or for other questions.